The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A Review
Fengcui Sun,Xiufen Yang,Chaoqun Ma,Shizhao Zhang,Lu Yu,Haifei Lu,Guoliang Yin,Pengpeng Liang,Yanan Feng,Fengxia Zhang
DOI: https://doi.org/10.2147/DMSO.S326054
2021-09-15
Abstract:Fengcui Sun, 1 Xiufen Yang, 1 Chaoqun Ma, 1 Shizhao Zhang, 1 Lu Yu, 2 Haifei Lu, 3 Guoliang Yin, 1 Pengpeng Liang, 1 Yanan Feng, 1 Fengxia Zhang 4 1 Shandong University of Traditional Chinese Medicine, Jinan, 250000, People's Republic of China; 2 Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China; 3 Hubei University of Traditional Chinese Medicine, Wuhan, 430065, People's Republic of China; 4 Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, People's Republic of China Correspondence: Fengxia Zhang Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, People's Republic of China Tel +8653168616011 Email Hyperlipidemia is a disorder of lipid metabolism, which is a major cause of coronary heart disease. Although there has been considerable progress in hyperlipidemia treatment, morbidity and risk associated with the condition continue to rise. The first-line treatment for hyperlipidemia, statins, has multiple side effects; therefore, development of safe and effective drugs from natural products to prevent and treat hyperlipidemia is necessary. Diosgenin is primarily derived from fenugreek ( Trigonella foenum graecum ) seeds, and is also abundant in medicinal herbs such as Dioscorea rhizome, Dioscorea septemloba , and Rhizoma polygonati , is a well-known steroidal sapogenin and the active ingredient in many drugs to treat cardiovascular conditions. There is abundant evidence that diosgenin has potential for application in correcting lipid metabolism disorders. In this review, we evaluated the latest evidence related to diosgenin and hyperlipidemia from clinical and animal studies. Additionally, we elaborate the pharmacological mechanism underlying the activity of diosgenin in treating hyperlipidemia in detail, including its role in inhibition of intestinal absorption of lipids, regulation of cholesterol transport, promotion of cholesterol conversion into bile acid and its excretion, inhibition of endogenous lipid biosynthesis, antioxidation and lipoprotein lipase activity, and regulation of transcription factors related to lipid metabolism. This review provides a deep exploration of the pharmacological mechanisms involved in diosgenin-hyperlipidemia interactions and suggests potential routes for the development of novel drug therapies for hyperlipidemia. Keywords: diosgenin, hyperlipidemia, serum cholesterol, lipoprotein cholesterol, mechanism Hyperlipidemia is a pathological disorder of lipid metabolism that has various causes. The clinical manifestations of hyperlipidemia include increased serum cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C), and decreased serum high-density lipoprotein cholesterol (HDL-C). Imbalance of LDL-C and HDL-C can increase the risk of cardiovascular (CV) events, including myocardial infarction and stroke. 1 Data released by the American Heart Association in 2018 showed that CV disease (CVD) is the most lethal disease worldwide. 2 According to the 2010 global burden of disease study, 15.6 million people died of CVD, accounting for 29.6% of all deaths. 3 Hyperlipidemia has a long disease course, and many underlying causes, reflecting its complex etiology. 4 Dyslipidemia is a significant risk factor for coronary artery disease and stroke; hence, prevention and appropriate management of dyslipidemia can markedly lower the related morbidity and mortality. 5 Holven et al described the importance of early identification and treatment of patients with familial hypercholesterolemia for reducing cholesterol burden and risk of CHD. 6 Lipid-lowering therapy is a cornerstone of CV risk modification strategies, which can reduce LDL-C by 30–50% and proportionally reduce CV events. 7 Although statins are generally well tolerated, they are not always sufficient to achieve LDL-C goals for many patients, and cause numerous specific negative effects on muscle, liver, and kidney, as well as increasing the risk of new-onset diabetes mellitus and hemorrhagic stroke. 8,9 Therefore, there is an urgent need to develop new powerful drugs to treat hyperlipidemia and reduce the harms to human health and longevity worldwide associated with CV events. Natural products can facilitate a multi-component, multi-target, multi-channel, and multi-dimensional overall treatment networks. 10 Thus, natural products represent alternative resources for developing new drugs, with higher efficiency, better safety, and fewer side effects. 11 Moreover, nat -Abstract Truncated-
endocrinology & metabolism